臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| Total items :2822924
	Visitors : 30005671 Online Users : 1209 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library

Scope

Adv. Search

Login

Administrator

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"miller v a"

Return to Browse by Author
Sorting by Title	Sort by Date

Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2022-06-27T07:02:08Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A.
臺大學術典藏	2020-12-02T02:34:00Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A.
臺大學術典藏	2020-08-13T06:33:49Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.
臺大學術典藏	2020-05-26T09:27:07Z	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial	Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A.
臺大學術典藏	2020-05-26T09:27:07Z	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial	Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:27:06Z	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1	Chmielecki J; Lin Y.-L; Pan Y; Wang L; De Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; CHIH-HSIN YANG; Miller V.A; Riely G.J; Kris M.G; Engelman J.A; Vnencak-Jones C.L; Dias-Santagata D; Ladanyi M; Pao W.; Pao W.;Ladanyi M;Dias-Santagata D;Vnencak-Jones C.L;Engelman J.A;Kris M.G;Riely G.J;Miller V.A;Chih-Hsin Yang;Fidias P;Fernandez-Cuesta L;Kiura K;Toyooka S;Aoe K;Shien K;De Stanchina E;Wang L;Pan Y;Lin Y.-L;Chmielecki J;Moran T;Arcila M.E;Sequist L.V;Ohashi K; Ohashi K; Sequist L.V; Moran T; Arcila M.E
臺大學術典藏	2018-09-10T08:44:19Z	International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma	Brambilla, E.; Noguchi, M.; Nicholson, A.G.; Geisinger, K.R.; Yatabe, Y.; Beer, D.G.; Powell, C.A.; Riely, G.J.; Van Schil, P.E.; Garg, K.; Austin, J.H.M.; Asamura, H.; Rusch, V.W.; Hirsch, F.R.; Scagliotti, G.; Mitsudomi, T.; Huber, R.M.; Ishikawa, Y.; Jett, J.; Sanchez-Cespedes, M.; Sculier, J.-P.; Takahashi, T.; Tsuboi, M.; Vansteenkiste, J.; Wistuba, I.; Yang, P.-C.; Aberle, D.; Brambilla, C.; Flieder, D.; Franklin, W.; Gazdar, A.; Gould, M.; Hasleton, P.; Henderson, D.; Johnson, B.; Johnson, D.; Kerr, K.; Kuriyama, K.; Lee, J.S.; Miller, V.A.; Petersen, I.; Roggli, V.; Rosell, R.; Saijo, N.; Thunnissen, E.; Tsao, M.; Yankelewitz, D.; Travis, W.D.; PAN-CHYR YANGet al.
臺大學術典藏	2013	Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase iib/iii trial (lux-lung 1)	Hirsh V;Cadranel J;Cong X.J;Fairclough D;Finnern H.W;Lorence R.M;Miller V.A;Palmer M;Chih-Hsin Yang; Hirsh V; Cadranel J; Cong X.J; Fairclough D; Finnern H.W; Lorence R.M; Miller V.A; Palmer M; CHIH-HSIN YANG

Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page